Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer.

Literature DB >> 33527845

Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer.

Sonali M Smith¹, Kerri Wachter², Howard A Burris³, Richard L Schilsky², Daniel J George⁴, Douglas E Peterson⁵, Melissa L Johnson³, Merry Jennifer Markham⁶, Kathryn F Mileham⁷, Muhammad S Beg⁸, Johanna C Bendell³, Robert Dreicer⁹, Vicki L Keedy¹⁰, Randall J Kimple¹¹, Miriam A Knoll¹², Noelle LoConte¹¹, Helen MacKay¹³, Jane Lowe Meisel¹⁴, Timothy J Moynihan¹⁵, Daniel A Mulrooney¹⁶, Therese Marie Mulvey¹⁷, Olatoyosi Odenike¹, Nathan A Pennell¹⁸, Katherine Reeder-Hayes¹⁹, Cardinale Smith²⁰, Ryan J Sullivan¹⁷, Robert Uzzo²¹.

Abstract

Entities: Disease

Year: 2021 PMID： 33527845 DOI： 10.1200/JCO.20.03420

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

Keyword Cloud
Cited

× No keyword cloud information.

21 in total

1. Morpholine substituted quinazoline derivatives as anticancer agents against MCF-7, A549 and SHSY-5Y cancer cell lines and mechanistic studies.

Authors: Ashish Ranjan Dwivedi; Vijay Kumar; Vikash Prashar; Akash Verma; Naveen Kumar; Jyoti Parkash; Vinod Kumar
Journal: RSC Med Chem Date: 2022-04-05

Review 2. Immune Checkpoint Inhibitors in Cancer Therapy.

Authors: Yavar Shiravand; Faezeh Khodadadi; Seyyed Mohammad Amin Kashani; Seyed Reza Hosseini-Fard; Shadi Hosseini; Habib Sadeghirad; Rahul Ladwa; Ken O'Byrne; Arutha Kulasinghe
Journal: Curr Oncol Date: 2022-04-24 Impact factor: 3.109

Review 3. Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer.

Authors: Nicole M Myer; Kohei Shitara; Hyun C Chung; Florian Lordick; Ronan J Kelly; Zsolt Szabo; Z Alexander Cao; Stephen Leong; David H Ilson; Wilko Weichert
Journal: J Cancer Res Clin Oncol Date: 2022-05-13 Impact factor: 4.322

4. mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2',4'-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications.

Authors: Bashir Lawal; Ching-Yu Lee; Ntlotlang Mokgautsi; Maryam Rachmawati Sumitra; Harshita Khedkar; Alexander T H Wu; Hsu-Shan Huang
Journal: Front Oncol Date: 2021-03-26 Impact factor: 6.244

Review 5. Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer.

Authors: An Huang; Yong Yang; Jing-Yi Shi; Yu-Kun Li; Jing-Xuan Xu; Yu Cheng; Jin Gu
Journal: World J Gastrointest Surg Date: 2021-12-27

6. Retrospective analysis of the efficacy of adjuvant cytokine-induced killer cell immunotherapy combined with chemotherapy in colorectal cancer patients after surgery.

Authors: Xiao Li; Haodong Zhou; Wenwen Huang; Xuejuan Wang; Mingyao Meng; Zongliu Hou; Liwei Liao; Weiwei Tang; Yanhua Xie; Ruotian Wang; Haidong Yu; Liqiong Wang; Huirong Zhu; Wenju Wang; Jing Tan; Ruhong Li
Journal: Clin Transl Immunology Date: 2022-01-18

Review 10. Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers.

Authors: Semir Vranic; Zoran Gatalica
Journal: Bosn J Basic Med Sci Date: 2022-02-01 Impact factor: 3.363

Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer.

1. Morpholine substituted quinazoline derivatives as anticancer agents against MCF-7, A549 and SHSY-5Y cancer cell lines and mechanistic studies.

Review 2. Immune Checkpoint Inhibitors in Cancer Therapy.

Review 3. Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer.

4. mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2',4'-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications.

Review 5. Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer.

6. Retrospective analysis of the efficacy of adjuvant cytokine-induced killer cell immunotherapy combined with chemotherapy in colorectal cancer patients after surgery.

7. Selectively recommend ¹⁸F-FDG PET/CT for patients with de novo nasopharyngeal carcinoma in endemic areas.

Review 8. [Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer].

9. 'Strategic' development of precision cancer medicine in the United States.

Review 10. Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers.

Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer.

1. Morpholine substituted quinazoline derivatives as anticancer agents against MCF-7, A549 and SHSY-5Y cancer cell lines and mechanistic studies.

Review 2. Immune Checkpoint Inhibitors in Cancer Therapy.

Review 3. Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer.

4. mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2',4'-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications.

Review 5. Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer.

6. Retrospective analysis of the efficacy of adjuvant cytokine-induced killer cell immunotherapy combined with chemotherapy in colorectal cancer patients after surgery.

7. Selectively recommend 18F-FDG PET/CT for patients with de novo nasopharyngeal carcinoma in endemic areas.

Review 8. [Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer].

9. 'Strategic' development of precision cancer medicine in the United States.

Review 10. Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers.

7. Selectively recommend ¹⁸F-FDG PET/CT for patients with de novo nasopharyngeal carcinoma in endemic areas.